INTERCEPT is not approved for sale in the United States and certain other countries.

Switzerland

Customer Profile:
Service Régional Vaudois de Transfusion Sanguine (SRTS VD)

Date of INTERCEPT Implementation
2011: Apheresis and Buffy Coat Platelets

Annual Collections

• 31,000 whole blood collections

Annual INTERCEPT Production
• 3,000 units of platelet concentrates
  - 60% Apheresis
  - 40% Buffy Coat

www.mavietonsang.ch

Lausanne Workflow

Quality Control Data
SRTS VD maintains a rigorous QC program in order to ensure the final blood product characteristics are in compliance with national requirements.  The tables below include SRCS’s QC data for INTERCEPT treated apheresis and buffy coat platelets.

 

Table 1: SRTS VD QC Results for INTERCEPT Platelets - Apheresis
Parameter
INTERCEPT Platelets
(Average ± SD)
N
Volume (mL)
307 ± 4
30
Platelet count (x1011 plt/unit)
3.5 ± 0.1
30
pH (Day 5) 7.05 ± 0.27 30

Table 2: SRTS VD QC Results for INTERCEPT Platelets - Buffy Coat
Parameter
INTERCEPT Platelets
(Average ± SD)
N
Volume (mL)
328 ± 13
60
Platelet count (x1011 plt/unit)
3.4 ± 0.1
60
pH (Day 5) 6.92 ± 0.08 60

^ back to top




Lausanne Tissot quote 2

 

 

Untitled Document